Gastrointestinal stromal tumor( GIST ) is an uncommon entity in clinical practice. Though It is the commonest mesenchymal smooth muscle tumor, it accounts for only <1% of all GI malignancies. Any part of gastrointestinal tract (GIT ) may be involved . Stomach is the commonest site for this tumor. Other sites of GIT are also affected in this disease. Increasing awareness, newer diagnostic modalities and novel chemotherapeutic agents make the disease diagnosed earlier and successfully treated . Imatinib mesylate has changed the outcome of the disease .In Eastern part of India we have seen some cases over the years and expressed our observation here . Most of the patients were operated and later required Imatinib